{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:33Z","timestamp":1786982133616,"version":"build-2736575974"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To examine recent advances in understanding breast cancer brain metastases (BCBM), with emphasis on metastatic mechanisms, tumour-microenvironment interactions, receptor discordance between primary breast tumours and brain metastases, diagnostic innovations, and therapeutic strategies. The review sought to clarify how these developments inform precision management and identify priorities for future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>\n                      Studies implicate JAK\u2013STAT signalling, homologous recombination deficiency,\n                      <jats:italic>c-MYC<\/jats:italic>\n                      , PI3K\/AKT\/mTOR, and\n                      <jats:italic>RET<\/jats:italic>\n                      in BCBM progression. Tumour cells adapt via neuronal mimicry, metabolic reprogramming, and crosstalk with astrocytes and microglia. Receptor discordance between primary breast cancers and brain metastases occurs in up to one-third of cases and may alter systemic therapy. Emerging tools including liquid biopsy, spatial transcriptomics, and radiomics offer minimally invasive approaches for molecular profiling, spatial mapping, and imaging-based phenotyping to guide personalised management. Machine learning supports prognostication and imaging interpretation, though external validation is limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>BCBM reflect complex tumour-brain interactions. Advances in molecular understanding and diagnostics are beginning to inform the development of targeted therapies. Future work may benefit from integrating cancer neuroscience with computational modelling, standardise diagnostic platforms, and test the survival impact of receptor reassessment in prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01753-y","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:45:58Z","timestamp":1770306358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breast Cancer Brain Metastases: Current Understanding and Future Directions"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-8977","authenticated-orcid":false,"given":"Mohammad","family":"Alabdulrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon R.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhuja","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Almasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Benour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minatoullah","family":"Habaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cian M.","family":"Hehir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold DK.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Vare\u0161lija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"12","key":"1753_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12):991\u20131000.","journal-title":"Br J Cancer"},{"key":"1753_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/op.23.00794","author":"AS Raghavendra","year":"2024","unstructured":"Raghavendra AS, Ibrahim NK. Breast cancer brain metastasis: a comprehensive review. JCO Oncol Pract. 2024. https:\/\/doi.org\/10.1200\/op.23.00794.","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"1753_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","volume":"46","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957\u201367.","journal-title":"Immunity"},{"issue":"7","key":"1753_CR4","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","volume":"24","author":"N Priego","year":"2018","unstructured":"Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24(7):1024\u201335.","journal-title":"Nat Med"},{"issue":"3","key":"1753_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10555-020-09881-y","volume":"39","author":"M Hosonaga","year":"2020","unstructured":"Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020;39(3):711\u201320.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"1753_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s11912-024-01560-3","volume":"26","author":"GR Daly","year":"2024","unstructured":"Daly GR, Naidoo S, Alabdulrahman M, McGrath J, Dowling GP, AlRawashdeh MM, et al. Screening and testing for homologous recombination repair deficiency (HRD) in breast cancer: an overview of the current global landscape. Curr Oncol Rep. 2024;26(8):890\u2013903.","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"1753_CR7","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"1753_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-023-01488-0","volume":"26","author":"GR Daly","year":"2024","unstructured":"Daly GR, AlRawashdeh MM, McGrath J, Dowling GP, Cox L, Naidoo S, et al. PARP inhibitors in breast cancer: a short communication. Curr Oncol Rep. 2024;26(2):103\u201313.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1753_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41523-022-00395-0","volume":"8","author":"L Galland","year":"2022","unstructured":"Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, et al. Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing. NPJ Breast Cancer. 2022;8(1):28.","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"1753_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208\u201317.","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"1753_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000059341","volume":"95","author":"M Carter","year":"2001","unstructured":"Carter M, Yome J, Marcil M, Martin C, Vanhorne J, Mulligan L. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function. Cytogenet Cell Genet. 2001;95(3\u20134):169\u201376.","journal-title":"Cytogenet Cell Genet"},{"issue":"1","key":"1753_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239\u201354. e6.","journal-title":"Cell Rep"},{"issue":"5","key":"1753_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11912-025-01669-z","volume":"27","author":"M Habaka","year":"2025","unstructured":"Habaka M, Daly GR, Shinyanbola D, Alabdulrahman M, McGrath J, Dowling GP, et al. PARP inhibitors in the neoadjuvant Setting; A comprehensive overview of the rationale for their Use, past and ongoing clinical trials. Curr Oncol Rep. 2025;27(5):533\u201351.","journal-title":"Curr Oncol Rep"},{"key":"1753_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","volume":"184","author":"ME Robson","year":"2023","unstructured":"Robson ME, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39\u201347.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1753_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u201335.","journal-title":"Ann Oncol"},{"issue":"7","key":"1753_CR16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","volume":"30","author":"AD Staniszewska","year":"2024","unstructured":"Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, et al. Preclinical characterization of AZD9574, a Blood-Brain barrier penetrant inhibitor of PARP1. Clin Cancer Res. 2024;30(7):1338\u201351.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1753_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","volume":"22","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020;22(9):431\u201340.","journal-title":"Neoplasia"},{"key":"1753_CR18","unstructured":"A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06545942"},{"issue":"5","key":"1753_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","volume":"131","author":"HL Smith","year":"2024","unstructured":"Smith HL, Willmore E, Prendergast L, Curtin NJ. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer. 2024;131(5):905\u201317.","journal-title":"Br J Cancer"},{"key":"1753_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207710","author":"EM Me\u0161kyt\u0117","year":"2020","unstructured":"Me\u0161kyt\u0117 EM, Keskas S, Ciribilli Y. MYC as a multifaceted regulator of tumor microenvironment leading to metastasis. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21207710.","journal-title":"Int J Mol Sci"},{"key":"1753_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.791927","volume":"8","author":"B Liu","year":"2021","unstructured":"Liu B, Zhang X. Metabolic reprogramming underlying brain metastasis of breast cancer. Front Mol Biosci. 2021;8:791927.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"1753_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/1541-7786.MCR-18-0630","volume":"17","author":"HY Lee","year":"2019","unstructured":"Lee HY, Cha J, Kim SK, Park JH, Song KH, Kim P, et al. c-MYC drives breast cancer metastasis to the brain, but promotes synthetic lethality with TRAIL. Mol Cancer Res. 2019;17(2):544\u201354.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1753_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-025-02001-3","volume":"13","author":"AED Van Swearingen","year":"2025","unstructured":"Van Swearingen AED, Lee MR, Rogers LW, Sibley AB, Shi P, Qin X, et al. Genomic and immune profiling of breast cancer brain metastases. Acta Neuropathol Commun. 2025;13(1):99.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"1753_CR24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Mart\u00ednez-Mart\u00edn S, Foradada L, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30(3):762\u201371.","journal-title":"Nat Med"},{"issue":"1","key":"1753_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-024-00531-z","volume":"17","author":"K Li","year":"2024","unstructured":"Li K, Wang B, Hu H. Research progress of SWI\/SNF complex in breast cancer. Epigenetics & Chromatin. 2024;17(1):4.","journal-title":"Epigenetics & Chromatin"},{"key":"1753_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759577","volume":"11","author":"X Cheng","year":"2021","unstructured":"Cheng X, Zhao JX, Dong F, Cao XC. ARID1A mutation in metastatic breast cancer: a potential therapeutic target. Front Oncol. 2021;11:759577.","journal-title":"Front Oncol"},{"issue":"5","key":"1753_CR27","first-page":"1683","volume":"46","author":"T Wang","year":"2020","unstructured":"Wang T, Gao X, Zhou K, Jiang T, Gao S, Liu P, et al. Role of ARID1A in epithelial\u2013mesenchymal transition in breast cancer and its effect on cell sensitivity to 5\u2013FU. Int J Mol Med. 2020;46(5):1683\u201394.","journal-title":"Int J Mol Med"},{"issue":"2","key":"1753_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41588-019-0541-5","volume":"52","author":"S Nagarajan","year":"2020","unstructured":"Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, et al. ARID1A influences HDAC1\/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet. 2020;52(2):187\u201397.","journal-title":"Nat Genet"},{"key":"1753_CR29","unstructured":"Phase A. 1\/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05490472"},{"key":"1753_CR30","unstructured":"Phase A. II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04957615"},{"issue":"11","key":"1753_CR31","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1158\/1078-0432.CCR-18-3049","volume":"25","author":"FM Ippen","year":"2019","unstructured":"Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, et al. The dual PI3K\/mTOR pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-Mutant breast cancer brain metastases. Clin Cancer Res. 2019;25(11):3374\u201383.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1753_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11060-014-1369-6","volume":"117","author":"PF Peddi","year":"2014","unstructured":"Peddi PF, Hurvitz SA. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2\u2009+\u2009breast cancer. J Neurooncol. 2014;117(1):7\u201313.","journal-title":"J Neurooncol"},{"issue":"2","key":"1753_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"3","key":"1753_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","volume":"169","author":"RLB Costa","year":"2018","unstructured":"Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1753_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nrclinonc.2017.1","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn UE, Peiris-Pag\u00e9s M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(2):113.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1753_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361\u201371.","journal-title":"Cell"},{"issue":"11","key":"1753_CR37","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164\u201377.","journal-title":"Cancer Discov"},{"key":"1753_CR38","unstructured":"Open-label. Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a\/m) Breast Cancer Progressed to Anti-HER2 Based Therapy [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03767335"},{"key":"1753_CR39","unstructured":"Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive\/HER2-negative, PIK3CA\/PTEN-altered Breast Cancer Treated With Eribulin in Combination With MEN1611 [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05810870"},{"issue":"10","key":"1753_CR40","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/jnci\/djae091","volume":"116","author":"P Jagust","year":"2024","unstructured":"Jagust P, Powell AM, Ola M, Watson L, de Pablos-Aragoneses A, Garc\u00eda-G\u00f3mez P, et al. RET overexpression leads to increased brain metastatic competency in luminal breast cancer. J Natl Cancer Inst. 2024;116(10):1632\u201344.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1753_CR41","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/emmm.201302625","volume":"5","author":"A Gattelli","year":"2013","unstructured":"Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med. 2013;5(9):1335\u201350.","journal-title":"EMBO Mol Med"},{"issue":"20","key":"1753_CR42","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Solomon B, Loong HH, Park K, P\u00e9rol M, Arriola E, et al. First-Line Selpercatinib or chemotherapy and pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023;389(20):1839\u201350.","journal-title":"N Engl J Med"},{"issue":"15","key":"1753_CR43","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","volume":"27","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, et al. Intracranial efficacy of Selpercatinib in RET Fusion-Positive Non-Small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res. 2021;27(15):4160\u20137.","journal-title":"Clin Cancer Res"},{"key":"1753_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123087","volume":"357","author":"L Gao","year":"2024","unstructured":"Gao L, Zhang Y, Feng M, Shen M, Yang L, Wei B, et al. HER3: updates and current biology function, targeted therapy and pathologic detecting methods. Life Sci. 2024;357:123087.","journal-title":"Life Sci"},{"issue":"6","key":"1753_CR45","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.18632\/oncotarget.2846","volume":"6","author":"M Momeny","year":"2015","unstructured":"Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, et al. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6(6):3932\u201346.","journal-title":"Oncotarget"},{"issue":"1","key":"1753_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05445-8","volume":"22","author":"M Zhu","year":"2024","unstructured":"Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L, et al. HER3 receptor and its role in the therapeutic management of metastatic breast cancer. J Transl Med. 2024;22(1):665.","journal-title":"J Transl Med"},{"key":"1753_CR47","unstructured":"Phase 1b\/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06298084"},{"key":"1753_CR48","unstructured":"HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06172478"},{"key":"1753_CR49","unstructured":"A Phase IIa Study of Dendritic Cell Vaccines Against Her2\/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2\u2009+\u2009Breast Cancer (HER2\u2009+\u2009BC) or Hormone Receptor Positive (HR+) Breast Cancer [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04348747"},{"key":"1753_CR50","unstructured":"NICE. Advanced breast cancer: diagnosis and treatment: NICE. 2009 [updated 19 February 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/cg81\/chapter\/recommendations#diagnosis-and-assessment"},{"issue":"1130","key":"1753_CR51","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210944","volume":"95","author":"SH Derks","year":"2022","unstructured":"Derks SH, van der Veldt AA, Smits M. Brain metastases: the role of clinical imaging. Br J Radiol. 2022;95(1130):20210944.","journal-title":"Br J Radiol"},{"issue":"8","key":"1753_CR52","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11912-023-01432-2","volume":"25","author":"MA Roy-O\u2019Reilly","year":"2023","unstructured":"Roy-O\u2019Reilly MA, Lanman T, Ruiz A, Rogawski D, Stocksdale B, Nagpal S. Diagnostic and therapeutic updates in leptomeningeal disease. Curr Oncol Rep. 2023;25(8):937\u201350.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1753_CR53","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","volume":"29","author":"JP Glass","year":"1979","unstructured":"Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369\u201375.","journal-title":"Neurology"},{"key":"1753_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.critrevonc.2018.12.004","volume":"134","author":"M Cristofanilli","year":"2019","unstructured":"Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper. Crit Rev Oncol Hematol. 2019;134:39\u201345.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"1753_CR55","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/clinchem\/hvac127","volume":"68","author":"A Darlix","year":"2022","unstructured":"Darlix A, Cayrefourcq L, Pouderoux S, de Menjot Champfleur N, Bievelez A, Jacot W, et al. Detection of circulating tumor cells in cerebrospinal fluid of patients with suspected breast cancer leptomeningeal metastases: a prospective study. Clin Chem. 2022;68(10):1311\u201322.","journal-title":"Clin Chem"},{"key":"1753_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1472-6890-12-21","volume":"12","author":"E Le Rhun","year":"2012","unstructured":"Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt Mde C, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12:21.","journal-title":"BMC Clin Pathol"},{"issue":"3","key":"1753_CR57","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf S, Fritsche H, M\u00fcller V, Rau T, Schindlbeck C, Rack B, et al. Detection of Circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cellsearch system. Clin Cancer Res. 2007;13(3):920\u20138.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1753_CR58","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/neuonc\/noz012","volume":"21","author":"A Boire","year":"2019","unstructured":"Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol. 2019;21(5):571\u201384.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1753_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-024-02040-9","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T, et al. Advances in spatial transcriptomics and its applications in cancer research. Mol Cancer. 2024;23(1):129.","journal-title":"Mol Cancer"},{"key":"1753_CR60","first-page":"107","volume-title":"Biobanking: Methods and Protocols","author":"RS Tashjian","year":"2018","unstructured":"Tashjian RS, Vinters HV, Yong WH. Biobanking of cerebrospinal fluid. In: Biobanking: Methods and Protocols. 2018. p. 107\u201314."},{"key":"1753_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-020-0051-z","volume":"2","author":"H Tumani","year":"2020","unstructured":"Tumani H, Petereit H, Gerritzen A, Gross C, Huss A, Isenmann S, et al. S1 guidelines \u201clumbar puncture and cerebrospinal fluid analysis\u201d(abridged and translated version). Neurol Res Pract. 2020;2:1\u201328.","journal-title":"Neurol Res Pract"},{"key":"1753_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00045","volume":"8","author":"AE McEwen","year":"2020","unstructured":"McEwen AE, Leary SE, Lockwood CM. Beyond the blood: CSF-derived cfDNA for diagnosis and characterization of CNS tumors. Front Cell Dev Biol. 2020;8:45.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1753_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00550-1","volume":"9","author":"S Morganti","year":"2023","unstructured":"Morganti S, Parsons HA, Lin NU, Grinshpun A. Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer. NPJ Breast Cancer. 2023;9(1):43.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"1753_CR64","volume":"5","author":"R Klotz","year":"2022","unstructured":"Klotz R, Yu M. Insights into brain metastasis: recent advances in circulating tumor cell research. Cancer Rep. 2022;5(4):e1239.","journal-title":"Cancer Rep"},{"issue":"6","key":"1753_CR65","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41592-022-01480-9","volume":"19","author":"B Li","year":"2022","unstructured":"Li B, Zhang W, Guo C, Xu H, Li L, Fang M, et al. Benchmarking spatial and single-cell transcriptomics integration methods for transcript distribution prediction and cell type deconvolution. Nat Methods. 2022;19(6):662\u201370.","journal-title":"Nat Methods"},{"issue":"9","key":"1753_CR66","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrg3542","volume":"14","author":"E Shapiro","year":"2013","unstructured":"Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet. 2013;14(9):618\u201330.","journal-title":"Nat Rev Genet"},{"key":"1753_CR67","unstructured":"Yoo J, editor Genetic, landscape of brain metastasis in triple-negative-breast cancer: Comparison of paired primary and metastatic tumor using spatial transcriptomic analysis. Neuro-Oncology. 2024: Oxford Univ Press Inc Journals Dept, 2001 Evans RD, CARY, NC 27513 USA."},{"key":"1753_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1499301","volume":"15","author":"J An","year":"2024","unstructured":"An J, Lu Y, Chen Y, Chen Y, Zhou Z, Chen J, et al. Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy. Front Immunol. 2024;15:1499301.","journal-title":"Front Immunol"},{"issue":"1","key":"1753_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01728-y","volume":"25","author":"S Zhu","year":"2023","unstructured":"Zhu S, Zhang M, Liu X, Luo Q, Zhou J, Song M, et al. Single-cell transcriptomics provide insight into metastasis-related subsets of breast cancer. Breast Cancer Res. 2023;25(1):126.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1753_CR70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s44272-024-00018-8","volume":"3","author":"S Huang","year":"2024","unstructured":"Huang S, Ouyang L, Tang J, Qian K, Chen X, Xu Z, et al. Spatial transcriptomics: a new frontier in cancer research. Clin Cancer Bull. 2024;3(1):13.","journal-title":"Clin Cancer Bull"},{"issue":"3","key":"1753_CR71","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-024-07431-6","volume":"207","author":"GP Dowling","year":"2024","unstructured":"Dowling GP, Keelan S, Cosgrove NS, Daly GR, Giblin K, Toomey S, et al. Receptor discordance in metastatic breast cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Res Treat. 2024;207(3):471\u20136.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1753_CR72","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jnci\/djx273","volume":"110","author":"WA Schrijver","year":"2018","unstructured":"Schrijver WA, Suijkerbuijk KP, Van Gils CH, Van Der Wall E, Moelans CB, Van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(6):568\u201380.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1753_CR73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","volume":"50","author":"G Aurilio","year":"2014","unstructured":"Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50(2):277\u201389.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1753_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","volume":"7","author":"T Grinda","year":"2021","unstructured":"Grinda T, Joyon N, Lusque A, Lef\u00e8vre S, Arnould L, Penault-Llorca F, et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer. 2021;7(1):41.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"1753_CR75","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","volume":"22","author":"AFC Hulsbergen","year":"2020","unstructured":"Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22(8):1173\u201381.","journal-title":"Neuro Oncol"},{"key":"1753_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00099","volume":"9","author":"VA Venur","year":"2019","unstructured":"Venur VA, Cohen JV, Brastianos PK. Targeting molecular pathways in intracranial metastatic disease. Front Oncol. 2019;9:99.","journal-title":"Front Oncol"},{"issue":"3","key":"1753_CR77","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccr.2007.01.013","volume":"11","author":"M Shipitsin","year":"2007","unstructured":"Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259\u201373.","journal-title":"Cancer Cell"},{"key":"1753_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3630","volume":"16","author":"C Criscitiello","year":"2014","unstructured":"Criscitiello C, Andr\u00e9 F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, et al. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res. 2014;16:1\u20138.","journal-title":"Breast Cancer Res"},{"issue":"7341","key":"1753_CR79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature09807","volume":"472","author":"N Navin","year":"2011","unstructured":"Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90\u20134.","journal-title":"Nature"},{"issue":"5","key":"1753_CR80","first-page":"1557","volume":"29","author":"RJ Broom","year":"2009","unstructured":"Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O\u2019MALLEY FP, et al. Changes in Estrogen receptor, progesterone receptor and Her-2\/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 2009;29(5):1557\u201362.","journal-title":"Anticancer Res"},{"issue":"17","key":"1753_CR81","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1016\/j.ejca.2014.08.014","volume":"50","author":"E Karlsson","year":"2014","unstructured":"Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J. Breast cancer during follow-up and progression\u2013a population based cohort on new cancers and changed biology. Eur J Cancer. 2014;50(17):2916\u201324.","journal-title":"Eur J Cancer"},{"issue":"23","key":"1753_CR82","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","volume":"15","author":"EA Mittendorf","year":"2009","unstructured":"Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15(23):7381\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1753_CR83","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1524-4741.1999.97088.x","volume":"5","author":"LP Pertschuk","year":"1999","unstructured":"Pertschuk LP, Axiotis CA, Feldman JG, Kim YD, Karavattayhayyil SJ, Braithwaite L. Marked intratumoral heterogeneity of the proto-oncogene Her\u20102\/neu determined by three different detection systems. Breast J. 1999;5(6):369\u201374.","journal-title":"Breast J"},{"issue":"7","key":"1753_CR84","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/bjc.2016.34","volume":"114","author":"A Thomson","year":"2016","unstructured":"Thomson A, McGrane J, Mathew J, Palmer J, Hilton D, Purvis G, et al. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. Br J Cancer. 2016;114(7):793\u2013800.","journal-title":"Br J Cancer"},{"key":"1753_CR85","unstructured":"Dowling GP, Daly GR, Hegarty A, Flanagan M, Ola M, Fallon R et al. Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers. Cancer Commun."},{"key":"1753_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051413","author":"K Almstedt","year":"2023","unstructured":"Almstedt K, Krauthauser L, Kappenberg F, Wagner DC, Heimes AS, Battista MJ, et al. Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15051413.","journal-title":"Cancers (Basel)"},{"key":"1753_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr86","volume":"2","author":"AF Chambers","year":"2000","unstructured":"Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast cancer metastasis clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000;2:1\u20138.","journal-title":"Breast Cancer Res"},{"issue":"7265","key":"1753_CR88","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nature08489","volume":"461","author":"SP Shah","year":"2009","unstructured":"Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809\u201313.","journal-title":"Nature"},{"issue":"6","key":"1753_CR89","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","volume":"30","author":"E Amir","year":"2012","unstructured":"Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587\u201392.","journal-title":"J Clin Oncol"},{"key":"1753_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2771","volume":"12","author":"AM Thompson","year":"2010","unstructured":"Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res. 2010;12:1\u20139.","journal-title":"Breast Cancer Res"},{"key":"1753_CR91","doi-asserted-by":"crossref","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. Oxford University Press US; 2022.","DOI":"10.1200\/JCO.21.02314"},{"issue":"11","key":"1753_CR92","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332\u201347.","journal-title":"Ann Oncol"},{"issue":"11","key":"1753_CR93","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1159\/000518848","volume":"44","author":"EE Van Grinsven","year":"2021","unstructured":"Van Grinsven EE, Nagtegaal SH, Verhoeff JJ, Van Zandvoort MJ. The impact of stereotactic or whole brain radiotherapy on neurocognitive functioning in adult patients with brain metastases: a systematic review and meta-analysis. Oncol Res Treat. 2021;44(11):622\u201336.","journal-title":"Oncol Res Treat"},{"issue":"1","key":"1753_CR94","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4267673","volume":"2022","author":"W Shang","year":"2022","unstructured":"Shang W, Yao H, Sun Y, Mu A, Zhu L, Li X. Preventive effect of hippocampal sparing on cognitive dysfunction of patients undergoing whole-brain radiotherapy and imaging assessment of hippocampal volume changes. Biomed Res Int. 2022;2022(1):4267673.","journal-title":"Biomed Res Int"},{"key":"1753_CR95","unstructured":"Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5\u201320 Brain Metastases: A Phase III, Randomized Clinical Trial [Internet]. 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03075072"},{"issue":"2","key":"1753_CR96","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijrobp.2017.04.006","volume":"99","author":"RS Prabhu","year":"2017","unstructured":"Prabhu RS, Press RH, Patel KR, Boselli DM, Symanowski JT, Lankford SP, et al. Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: a multi-institutional analysis. Int J Radiation Oncology* Biology* Phys. 2017;99(2):459\u201367.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"4","key":"1753_CR97","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00066-024-02202-0","volume":"200","author":"KJ Borm","year":"2024","unstructured":"Borm KJ, Behzadi ST, H\u00f6rner-Rieber J, Krug D, Baumann R, Corradini S, et al. DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer. Strahlenther Onkol. 2024;200(4):259\u201375.","journal-title":"Strahlenther Onkol"},{"key":"1753_CR98","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-019-05309-6","volume":"177","author":"ME Melisko","year":"2019","unstructured":"Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res Treat. 2019;177:401\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1753_CR99","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023;9(2):197\u2013205.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1753_CR100","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(11):1537\u201370.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"1753_CR101","first-page":"2305","volume":"26","author":"R Bartsch","year":"2024","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neurooncology. 2024;26(12):2305\u201315.","journal-title":"Neurooncology"},{"issue":"12","key":"1753_CR102","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, et al. Trastuzumab Deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30(12):3717\u201327.","journal-title":"Nat Med"},{"key":"1753_CR103","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. New Engl J Med. 0(0)."},{"issue":"10","key":"1753_CR104","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/neuonc\/noab041","volume":"23","author":"W Wang","year":"2021","unstructured":"Wang W, He H, Mar\u00edn-Ramos NI, Zeng S, Swenson SD, Cho HY, et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021;23(10):1656\u201367.","journal-title":"Neuro Oncol"},{"issue":"5","key":"1753_CR105","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-20-2701","volume":"27","author":"M Shah","year":"2021","unstructured":"Shah M, Wedam S, Cheng J, Fiero MH, Xia H, Li F, et al. FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27(5):1220\u20136.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1753_CR106","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"key":"1753_CR107","first-page":"1638","volume":"17","author":"MC Gouveia","year":"2023","unstructured":"Gouveia MC, Hidalgo Filho CM, Moreno RA, Alves H, Ayres AS, Testa L, et al. Activity of capecitabine for central nervous system metastases from breast cancer. Ecancermedicalscience. 2023;17:1638.","journal-title":"Ecancermedicalscience"},{"issue":"27","key":"1753_CR108","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-Positive metastatic breast cancer previously treated with \u2265\u20092 HER2-Directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138\u201349.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1753_CR109","doi-asserted-by":"publisher","first-page":"e1327","DOI":"10.1002\/onco.13830","volume":"26","author":"SA Hurvitz","year":"2021","unstructured":"Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, et al. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist. 2021;26(8):e1327\u201338.","journal-title":"Oncologist"},{"issue":"5","key":"1753_CR110","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.esmoop.2022.100561","volume":"7","author":"R Wuerstlein","year":"2022","unstructured":"Wuerstlein R, Ellis P, Montemurro F, Ant\u00f3n Torres A, Delaloge S, Zhang Q, et al. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open. 2022;7(5):100561.","journal-title":"ESMO Open"},{"key":"1753_CR111","unstructured":"A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05673928"},{"issue":"10","key":"1753_CR112","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Ann Oncol. 2020;31(10):1350\u20138.","journal-title":"Ann Oncol"},{"key":"1753_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205132","author":"CJ Curtaz","year":"2022","unstructured":"Curtaz CJ, Kiesel L, Meybohm P, W\u00f6ckel A, Burek M. Anti-hormonal therapy in breast cancer and its effect on the blood-brain barrier. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14205132.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1753_CR114","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s13318-020-00635-3","volume":"45","author":"MG Conlan","year":"2020","unstructured":"Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S. Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women. Eur J Drug Metab Pharmacokinet. 2020;45(5):675\u201389.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1753_CR115","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002293","volume":"6","author":"A Sarfraz","year":"2025","unstructured":"Sarfraz A, Sarfraz M, Javad F, Khalid M, Shah B, Gul A, et al. Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis. Explor Target Antitumor Ther. 2025;6:1002293.","journal-title":"Explor Target Antitumor Ther"},{"key":"1753_CR116","unstructured":"Phase A. IB Study to evaluate the effect of RAD1901 on the availability of estrogen receptor binding sites in metastatic breast cancer lesions using 16\u03b1-18F-Fluoro-17\u03b2-Estradiol positron emission tomography imaging [Internet]. 2016. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02650817"},{"key":"1753_CR117","unstructured":"Phase A, Multicenter I, Open-Label. Multi-Part, Dose-escalation Study of RAD1901 in postmenopausal women with advanced estrogen receptor positive and HER2-negative breast cancer [Internet]. 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02338349"},{"issue":"12","key":"1753_CR118","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392(12):1189\u2013202.","journal-title":"N Engl J Med"},{"issue":"1","key":"1753_CR119","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11060-016-2275-x","volume":"131","author":"P Chabot","year":"2017","unstructured":"Chabot P, Hsia TC, Ryu JS, Gorbunova V, Belda-Iniesta C, Ball D, et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol. 2017;131(1):105\u201315.","journal-title":"J Neurooncol"},{"issue":"4","key":"1753_CR120","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497\u2013509.","journal-title":"Lancet Oncol"},{"issue":"36","key":"1753_CR121","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1753_CR122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/cns.12.13","volume":"1","author":"R Carruthers","year":"2012","unstructured":"Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol. 2012;1(1):85\u201397.","journal-title":"CNS Oncol"},{"issue":"21","key":"1753_CR123","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1158\/1078-0432.CCR-24-1161","volume":"30","author":"A Giordano","year":"2024","unstructured":"Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, et al. A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer. Clin Cancer Res. 2024;30(21):4856\u201365.","journal-title":"Clin Cancer Res"},{"key":"1753_CR124","unstructured":"Phase A. II Study of atezolizumab in combination with pertuzumab plus high-dose trastuzumab for the treatment of central nervous system metastases in patients with Her2-positive breast cancer [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03417544"},{"key":"1753_CR125","unstructured":"Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06418594"},{"key":"1753_CR126","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2020.12.043","volume":"502","author":"S Zhou","year":"2021","unstructured":"Zhou S, Xie J, Huang Z, Deng L, Wu L, Yu J, et al. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges. Cancer Lett. 2021;502:166\u201379.","journal-title":"Cancer Lett"},{"issue":"10","key":"1753_CR127","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41556-024-01509-5","volume":"26","author":"AE Yuzhalin","year":"2024","unstructured":"Yuzhalin AE, Lowery FJ, Saito Y, Yuan X, Yao J, Duan Y, et al. Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol. 2024;26(10):1773\u201389.","journal-title":"Nat Cell Biol"},{"key":"1753_CR128","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.11.045","volume":"145","author":"H Li","year":"2021","unstructured":"Li H, Wang J, Yi Z, Li C, Wang H, Zhang J, et al. CDK12 Inhibition enhances sensitivity of HER2\u2009+\u2009breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K\/AKT. Eur J Cancer. 2021;145:92\u2013108.","journal-title":"Eur J Cancer"},{"key":"1753_CR129","unstructured":"Modular A, Multi-Part M-A. Phase 1\/2 Study to evaluate the safety and tolerability of CT7439 alone and in combination with anticancer treatments in participants with solid malignancies [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06600789"},{"key":"1753_CR130","doi-asserted-by":"publisher","first-page":"e2300639","DOI":"10.1200\/PO.23.00639","volume":"8","author":"T Bhogal","year":"2024","unstructured":"Bhogal T, Giannoudis A, Sokol E, Ali S, Palmieri C. Analysis of breast cancer brain metastases reveals an enrichment of Cyclin-Dependent kinase 12 structural rearrangements in human epidermal growth factor receptor 2\u2013Positive disease. JCO Precis Oncol. 2024;8:e2300639.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"1753_CR131","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2767-9764.CRC-22-0492","volume":"3","author":"A Morikawa","year":"2023","unstructured":"Morikawa A, Li J, Ulintz P, Cheng X, Apfel A, Robinson D, et al. Optimizing precision medicine for breast cancer brain metastases with functional drug response assessment. Cancer Res Commun. 2023;3(6):1093\u2013103.","journal-title":"Cancer Res Commun"},{"issue":"9","key":"1753_CR132","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab Deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1753_CR133","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12967-023-04277-2","volume":"21","author":"C Li","year":"2023","unstructured":"Li C, Liu M, Zhang Y, Wang Y, Li J, Sun S, et al. Novel models by machine learning to predict prognosis of breast cancer brain metastases. J Transl Med. 2023;21(1):404.","journal-title":"J Transl Med"},{"issue":"1","key":"1753_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66658-x","volume":"14","author":"Y Tan","year":"2024","unstructured":"Tan Y, Zhang W-h, Huang Z, Tan Q-x, Zhang Y-m, Wei C-y, et al. AI models predicting breast cancer distant metastasis using LightGBM with clinical blood markers and ultrasound maximum diameter. Sci Rep. 2024;14(1):15561.","journal-title":"Sci Rep"},{"key":"1753_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/genes14091768","author":"A Shiner","year":"2023","unstructured":"Shiner A, Kiss A, Saednia K, Jerzak KJ, Gandhi S, Lu FI, et al. Predicting patterns of distant metastasis in breast cancer patients following local regional therapy using machine learning. Genes. 2023. https:\/\/doi.org\/10.3390\/genes14091768.","journal-title":"Genes"},{"issue":"1","key":"1753_CR136","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jmri.26766","volume":"51","author":"E Gr\u00f8vik","year":"2020","unstructured":"Gr\u00f8vik E, Yi D, Iv M, Tong E, Rubin D, Zaharchuk G. Deep learning enables automatic detection and segmentation of brain metastases on multisequence MRI. J Magn Reson Imaging. 2020;51(1):175\u201382.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"1753_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101085","volume":"8","author":"H Ziyaee","year":"2023","unstructured":"Ziyaee H, Cardenas CE, Yeboa DN, Li J, Ferguson SD, Johnson J, et al. Automated brain metastases segmentation with a deep dive into false-positive detection. Adv Radiat Oncol. 2023;8(1):101085.","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"1753_CR138","first-page":"e190047","volume":"2","author":"R Forghani","year":"2020","unstructured":"Forghani R. Precision digital oncology: emerging role of radiomics-based biomarkers and artificial intelligence for advanced imaging and characterization of brain tumors. Radiology: Imaging Cancer. 2020;2(4):e190047.","journal-title":"Radiology: Imaging Cancer"},{"issue":"1","key":"1753_CR139","doi-asserted-by":"publisher","first-page":"vdac141","DOI":"10.1093\/noajnl\/vdac141","volume":"4","author":"A Nowakowski","year":"2022","unstructured":"Nowakowski A, Lahijanian Z, Panet-Raymond V, Siegel PM, Petrecca K, Maleki F, et al. Radiomics as an emerging tool in the management of brain metastases. Neuro-Oncology Adv. 2022;4(1):vdac141.","journal-title":"Neuro-Oncology Adv"},{"key":"1753_CR140","doi-asserted-by":"publisher","first-page":"110830","DOI":"10.1016\/j.ejrad.2023.110830","volume":"163","author":"B Kocak","year":"2023","unstructured":"Kocak B, Bulut E, Bayrak ON, Okumus AA, Altun O, Borekci Arvas Z, et al. NEgatiVE results in radiomics research (NEVER): A meta-research study of publication bias in leading radiology journals. Eur J Radiol. 2023;163:110830.","journal-title":"Eur J Radiol"},{"issue":"1","key":"1753_CR141","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13014-023-02246-z","volume":"18","author":"JY Wang","year":"2023","unstructured":"Wang JY, Qu V, Hui C, Sandhu N, Mendoza MG, Panjwani N, et al. Stratified assessment of an FDA-cleared deep learning algorithm for automated detection and contouring of metastatic brain tumors in stereotactic radiosurgery. Radiat Oncol. 2023;18(1):61.","journal-title":"Radiat Oncol"},{"issue":"11","key":"1753_CR142","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1007\/s00330-022-08828-x","volume":"32","author":"Y Li","year":"2022","unstructured":"Li Y, Liu Y, Liang Y, Wei R, Zhang W, Yao W, et al. Radiomics can differentiate high-grade glioma from brain metastasis: a systematic review and meta-analysis. Eur Radiol. 2022;32(11):8039\u201351.","journal-title":"Eur Radiol"},{"issue":"3","key":"1753_CR143","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ccell.2023.12.018","volume":"42","author":"L Bejarano","year":"2024","unstructured":"Bejarano L, Kauzlaric A, Lamprou E, Lourenco J, Fournier N, Ballabio M, et al. Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. Cancer Cell. 2024;42(3):378\u201395. e10.","journal-title":"Cancer Cell"},{"issue":"8","key":"1753_CR144","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41416-021-01424-8","volume":"125","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ye F, Liang Y, Yang Q. Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. Br J Cancer. 2021;125(8):1056\u201367.","journal-title":"Br J Cancer"},{"issue":"3","key":"1753_CR145","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1073\/pnas.1322098111","volume":"111","author":"J Neman","year":"2014","unstructured":"Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A. 2014;111(3):984\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7775","key":"1753_CR146","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-019-1576-6","volume":"573","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019;573(7775):526\u201331.","journal-title":"Nature"},{"issue":"7604","key":"1753_CR147","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature18268","volume":"533","author":"Q Chen","year":"2016","unstructured":"Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma\u2013astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533(7604):493\u20138.","journal-title":"Nature"},{"issue":"12","key":"1753_CR148","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41556-023-01273-y","volume":"25","author":"KT Evans","year":"2023","unstructured":"Evans KT, Blake K, Longworth A, Coburn MA, Insua-Rodr\u00edguez J, McMullen TP, et al. Microglia promote anti-tumour immunity and suppress breast cancer brain metastasis. Nat Cell Biol. 2023;25(12):1848\u201359.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1753_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48740-0","volume":"15","author":"X Ruan","year":"2024","unstructured":"Ruan X, Yan W, Cao M, Daza RAM, Fong MY, Yang K, et al. Breast cancer cell-secreted miR-199b-5p hijacks neurometabolic coupling to promote brain metastasis. Nat Commun. 2024;15(1):4549.","journal-title":"Nat Commun"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01753-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:02:23Z","timestamp":1770310943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01753-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}